The Medical Cannabis and Wellness UCITS ETF - Acc

Why Invest in CBDX Medical Cannabis ETF?

A growing treatment for illnesses and diseases:

Medical cannabis can be used in the treatment of many of the world’s most pressing health concerns in cannabis including cancer, Alzheimer’s disease, glaucoma, epilepsy and chronic pain.  New research and increasing legalisation of cannabis use for medical purposes is creating more demand for pharmaceutical grade cannabis and related services.

Global growth of medical cannabis use:

With the full legalization of cannabis in Canada and regulatory reform in the US, more countries are adopting a legalization framework for use of medical cannabis.  As medical cannabis becomes more accepted, analysts expect the rate of cannabis reform to accelerate on a global scale.  

Targeted, legal, exposure to the medical cannabis industry:

CBDX provides targeted exposure to a new and growing industry of companies engaged in the production and associated services and products in the medical cannabis industry.  The fund has no explicit inclusion of big pharma companies in the index methodology to keep it focused on high exposure to the medical cannabis, hemp and CBD industry. Multiple levels of screening and oversight ensure companies in the index meet required laws, exchange listing rules and liquidity thresholds.

Risks

The Sub-Fund and the companies in which it invests may be subject to a higher degree of regulatory oversight and regulatory action, which may include a restriction on the types of companies that the Sub-Fund may invest in at any time

If a company becomes delisted from an exchange due to noncompliance with the rules and policies of the exchange, the Investment Manager will use reasonable endeavours to remove the company from the Sub-Fund's portfolio

The value of equities and equity-related securities can be affected by daily stock and currency market movements

Investors' capital is fully at risk and investors may not get back the amount originally invested

Exchange rate fluctuations could have a negative or positive effect on returns 6. Further risks are disclosed in the KIID and Prospectus